Intellia Therapeutics (NTLA) Receivables (2015 - 2026)
Intellia Therapeutics (NTLA) reported Receivables of $7.32 million for Q2 2026, down 35.5% from $11.35 million a year earlier and down 19.8% from the prior quarter.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Receivables (2015 - 2026) Analysis & Trends
At the end of FY2025, Intellia Therapeutics posted Receivables of $9.5 million, up 11.5% from FY2024.
- Receivables has a five-year compound annual growth rate of 17.6% (FY2020 to FY2025).
- By year, Receivables came in at $8.52 million in FY2024 (-77.3%), $37.46 million in FY2023 (+401.6%), $7.47 million in FY2022 (+250.4%) and $2.13 million in FY2021 (-49.6%).
- The Q2 2026 figure ranks as the lowest quarterly Receivables since Q2 2023.
- Year over year, Receivables gained in three of the last eight quarters, with an average decline of 18.8%.
- The high point for year-over-year Receivables in five years was Q4 2023 (growth of 401.6%); the low point was Q4 2024 (a decline of 77.3%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $9.13 million (Q1 2026), $9.5 million (Q4 2025) and $11.05 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 15.68 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 5.06 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 2.13 Bn |
| 10 | Intellia Therapeutics | 1.60 Bn | 1.60 Bn | - | 7.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.32 Mn |
| Mar 31, 2026 | 9.13 Mn |
| Dec 31, 2025 | 9.50 Mn |
| Sep 30, 2025 | 11.05 Mn |
| Jun 30, 2025 | 11.35 Mn |
| Mar 31, 2025 | 10.50 Mn |
| Dec 31, 2024 | 8.52 Mn |
| Sep 30, 2024 | 8.85 Mn |
| Jun 30, 2024 | 12.33 Mn |
| Mar 31, 2024 | 36.43 Mn |
| Dec 31, 2023 | 37.46 Mn |
| Sep 30, 2023 | 7.49 Mn |
| Jun 30, 2023 | 6.46 Mn |
| Mar 31, 2023 | 9.71 Mn |
| Dec 31, 2022 | 7.47 Mn |
| Sep 30, 2022 | 8.02 Mn |
| Jun 30, 2022 | 5.75 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 2.13 Mn |
| Sep 30, 2021 | 4.59 Mn |
API Access
Intellia Therapeutics Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=NTLA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "NTLA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=NTLA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();